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Endemic Burkitt lymphoma (eBL) is associated with Epstein–Barr virus (EBV) and Plasmodium falciparum coinfections. Malaria
appears to dysregulate immunity that would otherwise control EBV, thereby contributing to eBL etiology. Juxtaposed to human
genetic variants associated with protection from malaria, it has been hypothesized that such variants could decrease eBL sus-
ceptibility, historically referred to as “the protective hypothesis.” Past studies attempting to link sickle cell trait (HbAS), which
is known to be protective against malaria, with protection from eBL were contradictory and underpowered. Therefore, using a
case–control study design, we examined HbAS frequency in 306 Kenyan children diagnosed with eBL compared to 537 geo-
graphically defined and ethnically matched controls. We found 23.8% HbAS for eBL patients, which was not significantly dif-
ferent compared to 27.0% HbAS for controls [odds ratio (OR)50.85; 95% confidence interval (CI) 0.61–1.17; p-value50.33].
Even though cellular EBV titers, indicative of the number of latently infected B cells, were significantly higher (p-val-
ue<0.0003) in children residing in malaria holoendemic compared to hypoendemic areas, levels were not associated with
HbAS genotype. Combined, this suggests that although HbAS protects against severe malaria and hyperparasitemia, it is not
associated with viral control or eBL protection. However, based on receiver operating characteristic curves factors that enable
the establishment of EBV persistence, in contrast to those involved in EBV lytic reactivation, may have utility as an eBL pre-
cursor biomarker. This has implications for future human genetic association studies to consider variants influencing control
over EBV in addition to malaria as risk factors for eBL.
Endemic Burkitt lymphoma (eBL) is the most common pedi-
atric cancer in Equatorial Africa with a polymicrobial etiology
involving two ubiquitous pathogens, Epstein–Barr virus
(EBV) and Plasmodium falciparum.1,2 The syndemic relation-
ship between malaria and EBV coinfections has been associ-
ated with immune deﬁciencies in EBV-speciﬁc interferon-
gamma (IFN-g) memory recall responses, signiﬁcantly higher
peripheral blood EBV loads and perturbations in the B-cell
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compartment.3–6 Malarial parasites through cysteine-rich
interdomain region 1a (CIDR1-a) have been shown to
induce indiscriminant polyclonal B-cell proliferation accom-
panied by EBV lytic reactivation and an increase in the num-
ber of latently infected B cells.7 However, eBL is a rare event
(annual incidence 2 in 100,000 children1) relative to the prev-
alence of malaria and EBV infections within these pediatric
populations, suggesting that additional factors are involved in
its etiology.
Epidemiologic studies of eBL have not revealed signiﬁcant
family clusters, suggesting that risk does not appear to be
driven by highly penetrant mutations.8 This likely implies
that the main step in pathogenesis (e.g., 8; 14 translocation)
is a somatic event rather than a heritable trait. However, this
does not exclude the possibility that less penetrant common
variants are modiﬁers of the overall risk of eBL providing a
more permissive or susceptible background. For instance,
genome-wide studies of childhood acute lymphoblastic leuke-
mia have demonstrated a number of common genetic var-
iants that appear to alter risk.9 An obvious choice of
common variants that might impact eBL susceptibility is the
numerous mutations providing resistance to malaria. This
was ﬁrst suggested in the 1960s as “the protective hypothesis”
soon after the genetic polymorphism responsible for sickle
cell trait was discovered.10
Malaria appears to have been one of the strongest selective
forces to recently impact the human genome witnessed by
the numerous human gene mutations that confer a protective
advantage against falciparum malaria.11 One of the most
notable, the ﬁrst disease to have a proven molecularly deﬁned
mutation, is the point mutation in the beta-hemoglobin gene
creating sickle hemoglobin that polymerizes in deoxygenated
states.12 Homozygous individuals (HbSS) suffer from sickle
cell disease, whereas heterozygosity (HbAS, sickle cell trait)
confers protection against clinical malaria with 60% protec-
tion against high-density parasitemia13,14 and 70–90% protec-
tion against severe disease.15,16 If malaria disease severity and
level of parasitemia play a causal role in eBL etiology, it has
been postulated that the incidence of eBL would be lower in
those with sickle cell trait.10,17,18 Yet, the historical studies
examining the relative frequency of HbAS in eBL patients
compared to healthy children have yielded inconsistent ﬁnd-
ings. The ﬁrst published study from Nigeria in 1966 reported
that 95 eBL children had a signiﬁcantly lower frequency of
HbAS (17.9%) compared to 320 hospital-based controls
(29.7%, p-value5 0.03).17 However, HbAS was lower (25.6%)
in village-matched Yoruba controls rendering the difference
with eBL patients insigniﬁcant, p-value5 0.18.17 A second
smaller study from Uganda in 1970 supported the “protective
HbAS genotype hypothesis” but found that the HbAS fre-
quency between 36 eBL patients and 50 “neighbor controls”
was comparable (16.7 and 28.0%, respectively).10 The choice
of controls in the Nigerian study was questioned as biased
given the older age of the controls compared to the eBL
patients (HbAS frequency in the population may increase as
susceptible HbAA children succumb to malaria), and the
assumption that HbAS prevalence lacked substructure within
the Yoruban population despite varying levels of malaria
endemicity. A third study from Ghana in 1976 selected more
deﬁnitive control groups and compared HbAS frequency in
112 eBL patients to 78 age-matched neighbors (12.8 and
10.3%, respectively) and to 84 siblings (14.3 and 16.7%,
respectively). They concluded that HbAS frequency in eBL
patients did not differ from healthy controls.18
It has been 45 years since the “protective hypothesis” was
proposed suggesting that human genetic mutations that con-
fer protection against severe malaria would also be associated
with decreased eBL risk; yet this question has remained unre-
solved within the scientiﬁc community. With the advent of
advanced molecular techniques for quantifying and standard-
izing EBV load19,20 and renewed interest in directly studying
eBL patients in Africa,2 our study set forth to reinitiate inves-
tigations into the association between human genetic varia-
tions, EBV control and eBL risk starting with the most likely
candidate, sickle cell trait. We leveraged three groups of Ken-
yan children: those diagnosed with eBL, healthy children
residing in the same malaria holoendemic area where the
incidence of eBL is high and children from a hypoendemic
region where eBL incidence is low.21 Our ﬁrst objective was
to examine the HbAS frequency in eBL patients compared to
geographically matched holoendemic malaria-exposed con-
trols. Because of the ethnic heterogeneity within the eBL
patients, which has been previously described in Kenya22 but
was not described in previous studies of eBL, we also
matched our cases and controls on ethnicity. Furthermore,
we investigated the relationship between HbAS/AA genotype
and EBV loads, as a functional measure of viral control and
as a potential precursor biomarker for eBL risk.
What’s new?
Although the hypothesis dates back to 1970, studies of the “protective effect” of sickle cell trait (HbAS) on the development
of endemic Burkitt lymphoma (eBL) have led to contradictory conclusions. This new study analyzed an unprecedented number
of eBL cases and highlighted the importance of matching controls on ethnicity as well as malaria endemicity. The findings
contribute to resolving the controversy by showing that HbAS frequency does not differ between children diagnosed with eBL
and healthy children. The study also examined cellular Epstein-Barr Virus (EBV) titers, which in contrast to plasma EBV levels
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Material and Methods
Study populations
Between 2003 and 2012, children (aged 2–14 years, median
age 7 years, with a ratio of 1.5 males to females as previously
reported22) with a conﬁrmed diagnosis of eBL (n5 636) were
prospectively enrolled after informed consent from Nyanza
General Provincial Hospital (renamed the Jaramogi Oginga
Odinga Teaching and Referral Hospital in 2012), which is
the regional referral hospital for cancer treatment in western
Kenya. The catchment area for this hospital includes Provin-
ces formerly known as Nyanza, Rift Valley and Western
Provinces. Kenya was subdivided into counties in 2009 but
we will retain the older names that encompass broader
geographic areas. Histopathologic diagnosis was conﬁrmed by
two independent pathologists from ﬁne needle aspirations
stained with May-Grunewald Giemsa. An admission blood
sample was drawn before chemotherapy induction. The sam-
ple was used for hemoglobin levels measured on-site by port-
able b-hemoglobin photometer (Hemocue AB Angelholm,
Sweden) and the remainder was stored at 280C for DNA
extraction. HIV testing for all pediatric cancer patients is
standard of care at hospitals in Kenya. Patients enrolled in
this study with a diagnosis of eBL had a 1.3% HIV preva-
lence (unpublished ﬁnding). These eight children were
excluded from the analysis. On the basis of prior studies that
indicate the probability of sickle cell trait among controls is
0.2623 and the assumption that sickle cell trait protects
cases from cancer by a factor of 50% [odds ratio (OR) for
disease in HbAS relative to HbAA individuals is 0.5], we
would be able to reject the null hypothesis that the OR equals
1 with a power of 0.976 for Fisher’s exact test or corrected
chi-square test using a sample size of 337 cases and 537
controls.
Between 2005 and 2009, healthy controls (aged 2–14
years, median 6.7 years with a roughly equal number of
males as females) were enrolled from two rural areas of west-
ern Kenya, Nyanza (n5 547) and Rift Valley (n5 486) Prov-
inces, which have divergent malaria transmission patterns
and accordingly different incidences of eBL.21 Study sites
have been described in more detail elsewhere.3,21,24 In brief,
Nyanza residents experience stable and perennial P. falcipa-
rum transmission patterns (holoendemic malaria) and higher
eBL incidence, whereas residents from Rift Valley located at
high altitudes exceeding 3,000 m above sea level experience
low and sporadic P. falciparum transmission (hypoendemic
malaria) and lower eBL incidence.21 Healthy controls were
frequency matched on age range and malaria exposure and
enrolled by voluntary convenience sampling within each geo-
graphically deﬁned study site. Inclusion criteria consisted of
children having a normal full blood count and being EBV
seropositive. Hematological indices were compared across
study groups and values were within normal range for chil-
dren residing in Kenya.25 All children were EBV seropositive,
consistent with previous studies showing that primary infec-
tion occurs before the age of 3 years.3,24,26 Ethnicity of the
child was reported by the parent as part of the demographic
data collection survey.
Ethical approval
Ethical review and approval for this study was obtained from
the Institutional Review Board at The University of Massachu-
setts Medical School and the Ethical Review Committee at the
Kenya Medical Research Institute, Kenya. Parents of minor
study participants provided individual, written informed
consent.
Microscopic examination of P. falciparum
Whole blood was used for malaria parasite density determina-
tion. Giemsa-stained thick and thin blood smears were exam-
ined at 1,0003 under oil immersion. Malaria parasitemia was
quantiﬁed by counting the number of parasites per 200 leuko-
cytes and multiplying by 40, assuming an average white blood
cell count of 8,000 cells per microliter of blood, as per the
World Health Organization standard criteria.27 Any child test-
ing positive for blood-stage malaria parasites was treated free
of charge following the Kenya National Ministry of Health
Guidelines. All healthy control children were asymptomatic at
time of enrollment; therefore, any malaria infections were clas-
siﬁed as uncomplicated and treated accordingly.
PCR for sickle cell trait (HbAS)
HbAS trait was characterized as previously published.28
Brieﬂy, a 772-bp PCR product within the human beta-globin
gene was ampliﬁed from DNA extracted from whole blood
using the following primers: HbB1 (50-TCCTAAGCCAGTGC
CAGAAG-30) and HbB2 (50-GAATTCGTCTGTTTCCCATT
CTAAAC-30). The PCR amplicon was subsequently subjected
to restriction enzyme digestion using Bsu361 with resulting
fragment sizes visualized by horizontal gel electrophoresis. A
430-bp DNA fragment was found to be associated with the
mutant locus, whereas 228- and 202-bp DNA fragments were
generated from the normal locus.
Quantitative PCR for cellular and plasma EBV
Peripheral whole blood was collected by venipuncture under
sterile conditions. The plasma fraction was separated from
peripheral blood cells by centrifugation before freezing. The
cell pellet was then washed twice in sterile isotonic phosphate-
buffered saline and resuspended volume/volume then frozen
until batch DNA extraction was performed. DNA for cellular
EBV load was extracted from ethylenediaminetetraacetic acid
anticoagulated whole blood cell pellets, whereas DNA for EBV
viremia was measured from the plasma using QIAamp DNA
Mini Kit (Qiagen, Valencia, CA). Because of laboratory con-
straints DNA extraction could not be performed on plasma
samples before freezing. However, in an attempt to distinguish
free EBV DNA from lytic virions, plasma samples were ana-
lyzed before and after DNase I treatment.29 An aliquot of
plasma was digested with 5 U DNase I (Promega, Madison,
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incubated at 56C bath for 10 min. Viral quantiﬁcation was
then performed on DNA extracted from the peripheral blood
cell pellet and plasma before and after DNase I digestion as
previously described for EBV BALF51.19,24 The quantitative
(q)-PCR cycle was 3 min at 95C, 10 sec at 95C and 30 sec at
62.5C repeated for 40 cycles and read by a Bio-Rad CFX96TM
Real-Time System C1000TM Thermal Cycler base (BioRad Lab-
oratories, Hercules, CA). IQ Supermix (BioRad Laboratories)
was used for all reactions. Standard curves were generated
using EBV-positive Namalwa (American Type Cell Culture
Collection, USA, CRL-1432) and EBV-negative BL41 cell lines
(gift from Dr. Rosemary Rochford). Cellular viral loads were
normalized based on EBV genome copies per microgram of
human beta-actin DNA multiplexed23 in the qPCR assay,
whereas plasma viremia was normalized to EBV copies per
microliter of plasma. The lowest level of detection was calcu-
lated to be two EBV copies per microliter whole blood.
Statistical analysis
Chi-square tests and ORs with 95% conﬁdence intervals
(CIs) were used to test for differences in HbAS genotype fre-
quencies between cases and controls. Comparison of log-
transformed EBV load used a Kruskal–Wallis test, whereas
post hoc Dunn’s test was used to evaluate differences between
all pairs of viral loads between study populations. All tests
were two-tailed with p-values less than 0.05 considered statis-
tically signiﬁcant. Receiver operating characteristic (ROC)
curves and putative thresholds for EBV loads and other sta-
tistical analyses were performed using Graphpad Prism ver-
sion 5 (Graphpad Software, La Jolla, CA).
Results
Study population comparisons
As expected (Table 1), children from malaria holoendemic
areas were more likely to have a positive P. falciparum blood
smear with higher density infections compared to children
from a hypoendemic area (42 and 1%, respectively, p-value
<0.001). Only 19% of the eBL children were parasitemic by
blood smear on admission even though the vast majority
resided in malaria holoendemic areas.21 However, 28% of
parents reported their child having received antimalarial
treatment within the 2 weeks before referral to the cancer
ward. Of those with blood-stage parasitemia, geometric mean
parasite densities were signiﬁcantly lower for eBL patients
compared to asymptomatic malaria-infected children from
holoendemic areas (Table 1: 764 versus 1,098 parasites per
microliter of blood, p-value5 0.02, respectively).
Sickle cell trait does not protect against eBL for children
residing in malaria holoendemic areas after controlling for
ethnicity
Of the children with conﬁrmed eBL enrolled over a 10-year
period, 413 DNA samples collected during the same time
period as controls were screened for this study. Of those eBL
patients, 21.3% carried the HbAS genotype compared to
26.5% of the Nyanza malaria holoendemic controls (Table 1).
The odds of developing eBL hinted at being protective for
HbAS compared to HbAA when matched with geographically
deﬁned holoendemic malaria exposed children (OR5 0.75;
95% CI 0.55–1.02; p5 0.07) (Table 2). However, a more in-
depth investigation into the ethnicity of eBL patients revealed
a predominance of Luo (74.1%) yet with a signiﬁcant number
of Luhya (19.6%) and 6.3% from other self-reported ethnic-
ities relative to our controls who were predominantly Luo.
Therefore, Luo eBL patients (n5 306) were compared to Luo
controls (n5 537) rendering the OR for HbAS versus HbAA
not signiﬁcant [23.8 and 27.0% HbAS for Luo eBL patients
compared to Luo controls, respectively (Table 1); OR5 0.85;
95% CI 0.61–1.17; p-value5 0.33 (Table 2)]. We further
restricted our analysis to a smaller geographic area (nearest












microliter blood) HbAS frequency (%)
All eBL patients Holoendemic 413 19 7641 21.3
Luo eBL patients 306 23.8
Luhya eBL patients 81 15.9
Nyanza Province controls Holoendemic 547 42 1,0981 26.5
Luo controls 537 27.0
Rift Valley Province controls Hypoendemic 486 1 80 3.9
1Difference in P. falciparum malaria parasite density between eBL patients and controls from holoendemic area, p-value50.02.
Table 2. Odds ratios for developing eBL (HbAS against HbAA)
Group comparisons Odds ratio 95% CI p-Value
a) Holoendemic malaria controls and all eBL patients 0.75 0.55–1.02 0.07
b) Luo-matched controls and only Luo eBL patients 0.85 0.61–1.17 0.33
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neighbors). Matching both by district and ethnicity com-
pletely abrogated any apparent association between HbAS
frequency and eBL (Table 2). Sufﬁcient controls identiﬁed as
Luhya were not available within our control group. However,
using historical data, HbAS frequency among Luhya has been
reported at 12.5%,30 similar to 15.9% HbAS frequency we
observed for Luhya eBL patients (Table 1).
For the children from Nyanza Province, HbAS genotype
was associated with lower point-prevalence malaria parasite
density infections (geometric mean parasite density for HbAS
versus HbAA, 1,788 vs. 914 parasites per microliter of blood,
respectively) and was similar to other studies.31 This was not
assessed for the Rift Valley Province children owing to low
prevalence of infection and HbAS genotype or for eBL
patients who may have received antimalarial treatment before
enrollment. HbAS was infrequent in Rift Valley controls at
3.9% where malaria transmission is historically sporadic and
less intense.
EBV loads vary across study populations but are not
associated with HbAA/AS genotype
There is no empirical evidence indicating if measurements of
EBV infection dynamics are informative within the context of
eBL risk, although it has been shown that the age of primary
EBV infection occurs signiﬁcantly earlier in children residing
in malaria holoendemic areas compared to areas with lower
malaria incidence3,24,26 and circulating plasma EBV has been
associated with acute malaria infections.32 Additionally, hol-
oendemic malaria exposure has been associated with lack of
viral control.4,33–38 Therefore, we measured EBV from fractio-
nated peripheral blood samples and compared virus isolated
from the plasma (with and without DNase I digestion) and
cellular virus as an indicator of the number of latently
infected B cells.39 Within our previous studies of children
with eBL and those experiencing their primary EBV infection
within the ﬁrst few years of life,3,24 we measured EBV in
DNA isolated from whole bloods. Consistent with our previ-
ous studies, children with eBL had signiﬁcantly higher
median cellular viral loads compared to healthy control chil-
dren from Nyanza (14,810 versus 35.7 EBV copies per micro-
gram of human DNA, respectively, p-value< 0.0001) and
signiﬁcant differences existed between children from Nyanza
and Rift Valley (35.7 and 0.0 EBV copies per microgram of
human DNA, respectively, p-value5 0.0003).3 When we com-
pared EBV levels in the plasma, we found signiﬁcantly higher
viremia in eBL children (median 11,117 EBV copies per
microliter of plasma before DNase I digestion) compared to
healthy malaria holoendemic children (p-value< 0.0001).
However, median EBV plasma levels did not signiﬁcantly dif-
fer between children from Nyanza and Rift Valley (5.4 and
4.1 EBV copies per microliter of plasma, respectively). When
we compared the DNase I-treated plasma, viremia across
study groups demonstrated the same trend but was ﬁvefold
lower in concentration, suggesting a mixture of free viral
DNA and lytic virions as previously found in other EBV-
associated conditions.29 Plasma EBV levels before and after
DNAse I treatment in the healthy children were highly corre-
lated (r5 0.59, p-value< 0.001) and were not associated with
point-prevalence malaria parasitemia.
Next, we sought to determine whether EBV loads differed
by beta-hemoglobin genotype (HbAA/AS). As EBV levels
were signiﬁcantly higher in eBL patients, we examined groups
independently and then stratiﬁed by HbAA/AS genotypes.
We found no signiﬁcant differences in cellular EBV levels
Figure 1. Cellular EBV load stratified by HbAA/AS genotype. Cellular EBV levels were compared for (a) children diagnosed with eBL (n589),
(b) Nyanza (n5149) and (c) Rift Valley (n564) children after stratification by HbAA/AS genotype. There were no significant differences in
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based on beta-hemoglobin genotype for eBL patients (Fig.
1a) or healthy children from Nyanza (Fig. 1b) or Rift Valley
(Fig. 1c). HbAS was also not associated with differences in
plasma levels of EBV within any group (data not shown).
Correlation between cellular and plasma EBV levels
Past studies measuring peripheral EBV levels have quantiﬁed
virus from whole blood or plasma levels, yet few have ascer-
tained if viral compartment is informative for eBL risk.39
Therefore, we sought to assess the correlation between cellu-
lar and plasma EBV levels to determine if measuring virus
from one compartment was equally informative as the other
(Fig. 2). We found minimal correlation between viral levels
measured from cellular compared to plasma sources for chil-
dren who had been diagnosed with eBL (r5 0.243, p-val-
ue5 0.05), similar to other published studies.39 For healthy
children from malaria holoendemic areas, there was a signiﬁ-
cant albeit minimal correlation between cellular and plasma
virus (r5 0.177, p-value5 0.01), suggesting that although
latently infected B cells and lytic reactivation may be elevated
within the same children, their relative magnitude is not
commensurate. The lack of correlation for the children
drawn from Rift Valley was due to the signiﬁcantly lower
levels of cellular virus detected. Our observations are consist-
ent with a cross-sectional study measuring plasma and
whole-blood viral loads for 12 eBL patients from Malawi.39
We next assessed ROC curves comparing eBL cases to
malaria holoendemic controls to determine if EBV load
could be used as a predictive biomarker. We found the area
under the ROC to be 0.812 for cellular and 0.962 for plasma
levels (before DNase I treatment) both with a p-val-
ue< 0.0001. A cellular level of 1,000 EBV copies per micro-
gram of human DNA (3 log-fold) would provide 90%
speciﬁcity and 83% sensitivity, whereas plasma levels greater
than 120 EBV copies per microliter of plasma (2 log-fold)
would provide 90% speciﬁcity and 90% sensitivity. Compar-
ing children from Nyanza and Rift Valley, the area under
the ROC curve was 0.713 for cellular EBV (p-value< 0.0001)
but for EBV measured in the plasma the area under the
ROC curve was 0.553, p-value5 0.086, suggesting that cellu-
lar viral loads might be more informative for assessing eBL
risk than free viral DNA or lytic virions in the plasma. How-
ever, a level of 1,000 EBV copiers per microgram of human
DNA would provide 95% speciﬁcity with only 10% sensitiv-
ity. Figure 2 presents data on viral loads for both healthy
Nyanza children and eBL patients to visualize relative differ-
ences in cellular and plasma EBV levels (before DNase I
treatment) and suggests potential thresholds based on the
ROC analysis. Cellular EBV loads might serve as a more sen-
sitive biomarker of eBL risk than virus in the plasma, but
other factors would have to be included in the development
of a “BL risk score” to provide a reasonable false-positive
rate given the rarity of eBL.
Discussion
The primary objective of our study was to apply a sufﬁciently
powered sample set to examine the long-standing question of
whether sickle cell trait, which is associated with protection
Figure 2. Correlation between cellular and plasma EBV levels for healthy and eBL children. There was a significant correlation between cel-
lular and plasma EBV levels in healthy Kenyan children from Nyanza (triangle) r50.177, p-value50.010. Children diagnosed with eBL had
a nonsignificant correlation coefficient of r50.243, p-value50.05 (open circles). Based on the area under the ROC curve to assess sensi-
tivity and specificity, dashed lines at 2-log EBV copies per microliter of plasma and 3-log EBV copies per microgram of human DNA were
selected to visualize viral loads in healthy Kenyan children (triangle) and eBL patients (open circles) as a proposed threshold if either were
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from severe malaria and hyperparasitemia, decreases eBL
risk—referred to as the “protective hypothesis.”10,17 Genotyp-
ing an unprecedented number of children with conﬁrmed
diagnosis of eBL (n5 413), we found a frequency of 21.3%
HbAS. However, when compared to healthy children who
were matched for malaria exposure and ethnicity, the odds of
developing eBL were not signiﬁcantly associated with HbAA/
AS genotype (OR5 0.85; 95% CI 0.61–1.17, p-value5 0.33)
and this slight effect all but disappeared when eBL cases were
matched by district (neighborhood controls). This suggests
that eBL risk is not signiﬁcantly predicated on HbAA/AS
genotype to the same degree as the protective effect it engen-
ders for malaria in terms of severe disease and hyperparasite-
mia.40 Although it is certainly possible that HbAS exerts a
small effect given the range of our CIs, in light of its lack of
association with EBV load it is more likely that eBL pathoge-
nesis is due to malaria-induced immunological dysregulation,
which is not impacted by this structural mutation in hemo-
globin beta chain.
Sickle cell trait signiﬁcantly protects children from the
clinically severe manifestations of malaria that can result in
death before the age of 5 years41,42 but does not protect a
child from all malaria infections. Children with sickle cell
trait are able to harbor asymptomatic parasitemias, which
ﬁts with our current model of eBL pathogenesis. Further-
more, as the incidence of eBL in Kenya peaks between 5
and 9 years of age, we propose that acute uncomplicated
and/or chronic asymptomatic malaria infections have a
more profound impact on EBV persistence and subsequent
risk of eBL than severe malaria (reviewed in Ref. 43). A
syndemic model for EBV and malaria related to the pro-
gression of eBL pathogenesis over time is corroborated by
our clinical data collected prospectively on more than 600
children diagnosed with eBL in western Kenya, whose
parents reported their child’s ﬁrst severe illness was pre-
senting to hospital with cancer—not severe malaria (Moor-
mann, unpublished data).
Our secondary aim was to measure peripheral EBV load
as an indicator of viral control and associate levels with
HbAA/AS genotype. Within this study, we conﬁrmed that
signiﬁcantly higher median cellular EBV levels existed in
malaria-exposed compared to nonexposed children3 but these
levels were not associated with HbAS genotype. Differences
in peripheral EBV level were apparent for cellular virus but
not plasma viremia (i.e., free viral DNA or lytic virions), sug-
gesting that measuring the frequency of latently infected B
cells could be exploited as a minimally invasive biomarker
for eBL risk.
The annual incidence of eBL in western Kenya is 2–5
per 100,000 children22 making it orders of magnitude less
frequent than the ubiquitous coinfections implicated in its
etiology. Therefore, an easily measured biomarker would be
of use to identify children at risk for eBL. EBV loads have
the potential to be used as predictive and prognostic bio-
markers once a child has been diagnosed with eBL. Studies
of EBV-associated malignancies such as non-Hodgkin’s lym-
phoma, post-transplant lymphoproliferative disorders and
nasopharyngeal carcinoma have measured EBV levels,44–48
providing a clinically useful metric for monitoring disease
regression or as a harbinger of relapse. To date, no such
studies had been carried out to evaluate EBV levels as prog-
nostic indicators for eBL.
Our lack of association with HbAS does not preclude
other malaria-associated host genetic variants having protec-
tive effects for eBL or viral control. Rather, we would suggest
that traits associated with eBL pathogenesis, such as immune
modulation of malaria that allows this infection to remain
asymptomatic (and therefore chronic), will be more likely to
inﬂuence risk than protective variants due to structural alter-
ations of the red cell that inhibit parasite growth. Addition-
ally, other immune-modulating human genetic variants
unrelated to malaria may be important for viral control and
eBL risk. In addition, eBL risk may be associated with
genomic instability given the requisite c-myc-Ig chromo-
somal translocation. This is supported by examples of com-
mon genetic variants being associated with acute
lymphoblastic leukemia that has no known infectious risk
factor.9 Therefore, a combinatorial model for eBL etiology
emerges that incorporates human genetic variation as well as
factors that inﬂuence immunity to EBV during malaria
coinfections.
This study although having a large enough sample size
had two limitations. The case–control study design was
unable to capture the longitudinal changes in EBV infection
dynamics as a consequence of repeated malaria infections.
However, this limitation may be addressed by the fact that
the study populations resided in areas of western Kenya with
well-deﬁned malaria endemicity, thus allowing us to make
conclusions about the effect of cumulative malaria exposure
on EBV persistence. Furthermore, our longitudinal studies
recently reported that primary EBV infections occur at a sig-
niﬁcantly younger age in children residing in a malaria hol-
oendemic area compared to a hypoendemic area, 7.28
compared to 8.39 months of age, respectively, and that 35%
of children resident in Kisumu experience primary EBV
infection before 6 months of age.24 The cumulative-negative
impact of chronic malaria on EBV control is supported by a
recent study from The Gambia, where malaria control pro-
grams have been very successful, showing that residents were
no longer impaired as measured by classical EBV regression
assay49—in contrast to their earlier studies conducted in 1984
when malaria transmission was high.34 The second limitation
is the appropriate choice of controls. We selected geographi-
cally and ethnicity matched controls; however, malaria-
exposure history, selective pressure and thus allele frequencies
can vary within microenvironments.21 Therefore, future stud-
ies should strive to include sibling and parent–child matches
necessary for deﬁnitive genetic comparisons as well as the
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In summary, this study concludes that HbAS genotype
does not confer protection against eBL. This is consistent
with the lack of an effect for HbAS genotype on peripheral
blood EBV levels within the eBL-at-risk malaria holoendemic
controls. In addition, plasma EBV levels (i.e., free viral DNA
or lytic virions) do not have predictive power to serve as an
eBL biomarker. However, high levels of cellular EBV (i.e.,
latently infected B cells) may have utility as a precursor for
eBL in combination with other risk factors. This study does
not eliminate a role for human genetics/genomics in eBL
pathogenesis but supports a more encompassing syndemic
model that includes modulations of the host response to
EBV during malaria coinfections.
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